Takeda Pharmaceutical (TAK) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock TAK Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Alerts: Takeda Report Highlights Company's Commitment to Cutting-Edge Science, Putting Patients FirstJuly 10 at 12:55 PM | finanznachrichten.deDengue vaccine maker explains withdrawal of US, Singapore applicationsJuly 3, 2025 | msn.comDengue vaccine maker awaiting Philippines approvalJuly 3, 2025 | msn.comTakeda Pharmaceutical Co., Ltd. (4502) - Investing.comJuly 1, 2025 | investing.comTakeda Pharmaceutical ADR Earns RS Rating UpgradeJuly 1, 2025 | msn.comFDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiencyJuly 1, 2025 | finance.yahoo.comTakeda Pharmaceuticals Gets FDA Approval for Liquid GammagardJune 30, 2025 | marketwatch.comLupin launches Prucalopride tablets in U.S. marketJune 26, 2025 | msn.comLupin receives USFDA approval for generic Prucalopride tabletsJune 25, 2025 | msn.comLupin gets USFDA nod for new constipation drug, stock gainsJune 25, 2025 | msn.comLabviva Showcases Advanced AI Procurement Tools at the R&D Procurement and Sourcing in Pharma Summit 2025June 19, 2025 | tmcnet.comPSCI Endorses My Green Lab's Converge Supplier Initiative To Cut Scope 3 Emissions in PharmaJune 18, 2025 | finance.yahoo.comExperts urge PH gov’t to expedite approval of new dengue vaccineJune 17, 2025 | msn.comJapan Credit Sales See Busiest June in Years as Buyers Seek RiskJune 11, 2025 | bloomberg.com‘United Against Dengue’ alliance launched to combat surge in casesJune 11, 2025 | msn.comSimultaneously visualizing electrical and calcium dynamics in patient iPSC-derived heart muscle cellsJune 10, 2025 | msn.comEC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphomaJune 4, 2025 | finance.yahoo.comCell & Gene Therapies in Dermatology Disorders | Develop Robust In-Licensing Strategies in the Face of GI CGT Market ChangesMay 30, 2025 | finance.yahoo.comTakeda Pharmaceutical Stock Price HistoryMay 27, 2025 | investing.comHealth Rounds: Older diabetes drugs appear to slow prostate cancer in small studyMay 21, 2025 | msn.comDrugmakers rebound after White House eases fears over Trump’s drug pricing orderMay 14, 2025 | msn.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2024 Earnings Call TranscriptMay 10, 2025 | msn.comTakeda Pharmaceutical FY Net Profit Missed Y134.71B Expected in Poll of Analysts by Quick >4502.TOMay 8, 2025 | marketwatch.comWhat To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 EarningsMay 7, 2025 | finance.yahoo.comAustralia's CSL evaluates China tariff exemptions for its US-made drugsApril 30, 2025 | msn.comJapan's Takeda to launch dengue vaccine in India with Biological E next yearApril 28, 2025 | msn.comCHMP gives positive opinion on variation to marketing authorization for AdcetrisApril 27, 2025 | markets.businessinsider.comRI biotech hires exec to launch new eye therapy in U.S. marketApril 24, 2025 | bizjournals.comDelveInsight Business Research, LLP: Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsightApril 15, 2025 | finanznachrichten.deTrump’s tariff tirade and sudden calm keep Big Pharma on its toesApril 10, 2025 | finance.yahoo.comAsian Equities Traded in the US as American Depositary Receipts Fall in Thursday TradingApril 3, 2025 | msn.comUK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma PatientsApril 2, 2025 | benzinga.comTakeda & Protagonist: Rusfertide Clinical Success Bolsters Investment ReturnsApril 1, 2025 | seekingalpha.comAxsome's drug scores modest win after improving ADHD symptoms in studyMarch 25, 2025 | msn.comAxsome's ADHD drug meets main goal in late-stage studyMarch 25, 2025 | msn.comBenchmark Initiates Coverage of Kamada (KMDA) with Buy RecommendationMarch 22, 2025 | msn.comTakeda Pharmaceutical Co Ltd (TAK) Announces Positive Phase 3 Results for Rusfertide in ...March 3, 2025 | gurufocus.comEMA approves Takeda’s Takhzyro pre-filled pen option for HAEFebruary 25, 2025 | msn.comTakeda broadens its deal with BridGene for up to $770mFebruary 25, 2025 | finance.yahoo.comEpilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsightFebruary 20, 2025 | finance.yahoo.comIn an uncertain world, CEOs seek growth while bracing for disruptionFebruary 20, 2025 | msn.comInside Takeda’s Plasma-Derived Therapy EcosystemFebruary 13, 2025 | forbes.comCOUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 DiabetesFebruary 4, 2025 | markets.businessinsider.comTakeda Pharmaceutical: Strong Financials, Strategic Leadership Change, and Robust Pipeline Justify Buy RatingJanuary 31, 2025 | markets.businessinsider.comTakeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic MovesJanuary 31, 2025 | markets.businessinsider.comDrugmaker Takeda's CEO Weber to step down, raises profit forecastJanuary 30, 2025 | msn.comTakeda CEO Christophe Weber to retire in 2026, Julie Kim to succeedJanuary 30, 2025 | markets.businessinsider.comTakeda gains after FY24 guidance raise, CEO transitionJanuary 30, 2025 | msn.comTakeda 9-Month EPS Rises, Revises FY24 Outlook, Julie Kim To Be New CEOJanuary 30, 2025 | markets.businessinsider.comTakeda Pharmaceutical Names U.S. Head Julie Kim as Next CEOJanuary 30, 2025 | msn.com Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address TAK Media Mentions By Week TAK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.511.55▲Average Manufacturing News Sentiment TAK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼12▲TAK Articles Average Week Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBH News Today BHC News Today CRON News Today TLRY News Today AIM News Today CRDL News Today ITH News Today APM News Today GXE News Today MDNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:TAK) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAK Stock Alerts